Department of Biological Sciences, University of South Carolina, Columbia, SC 29208, USA.
Center for Childhood Neurotherapeutics, University of South Carolina, Columbia, SC 29208, USA.
Sci Transl Med. 2021 Feb 10;13(580). doi: 10.1126/scitranslmed.aaw0682.
Christianson syndrome (CS), an X-linked neurological disorder characterized by postnatal attenuation of brain growth (postnatal microcephaly), is caused by mutations in , the gene encoding endosomal Na/H exchanger 6 (NHE6). To hasten treatment development, we established induced pluripotent stem cell (iPSC) lines from patients with CS representing a mutational spectrum, as well as biologically related and isogenic control lines. We demonstrated that pathogenic mutations lead to loss of protein function by a variety of mechanisms: The majority of mutations caused loss of mRNA due to nonsense-mediated mRNA decay; however, a recurrent, missense mutation (the G383D mutation) had both loss-of-function and dominant-negative activities. Regardless of mutation, all patient-derived neurons demonstrated reduced neurite growth and arborization, likely underlying diminished postnatal brain growth in patients. Phenotype rescue strategies showed mutation-specific responses: A gene transfer strategy was effective in nonsense mutations, but not in the G383D mutation, wherein residual protein appeared to interfere with rescue. In contrast, application of exogenous trophic factors (BDNF or IGF-1) rescued arborization phenotypes across all mutations. These results may guide treatment development in CS, including gene therapy strategies wherein our data suggest that response to treatment may be dictated by the class of mutation.
克里斯蒂安森综合征(CS)是一种 X 连锁的神经发育障碍,其特征为出生后大脑生长减弱(出生后小头畸形),由内体 Na+/H+交换蛋白 6(NHE6)基因编码基因突变引起。为了加速治疗开发,我们建立了 CS 患者的诱导多能干细胞(iPSC)系,代表了一个突变谱,以及具有生物学相关性和同基因对照系。我们证明,致病性突变通过多种机制导致蛋白功能丧失:大多数突变导致由于无义介导的 mRNA 降解而丧失 mRNA;然而,一个反复出现的错义突变(G383D 突变)具有失活和显性负性活性。无论突变如何,所有患者来源的神经元均表现出神经突生长和分支减少,这可能是患者出生后大脑生长减弱的基础。表型挽救策略显示出突变特异性反应:基因转移策略对无义突变有效,但对 G383D 突变无效,其中残留蛋白似乎干扰了挽救。相比之下,外源性营养因子(BDNF 或 IGF-1)的应用可挽救所有突变的分支表型。这些结果可能指导 CS 的治疗开发,包括基因治疗策略,我们的数据表明,治疗反应可能取决于突变类型。